Moderna Inc

NASDAQ:MRNA   3:59:59 PM EDT
123.70
-0.62 (-0.50%)
Products, Regulatory

Moderna Reviews Clinical Trial Programs Across Portfolio

Published: 09/09/2022 03:56 GMT
Moderna Inc (MRNA) - Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 Research and Development Day.
Moderna - Interim Data From Phase 1/2 Propionic Acidemia Multi-dose Paramount Trial Shows Mrna-3927 Was Well-tolerated to Date.
Moderna - Interim Data From Phase 1/2 Glycogen Storage Disease 1a (gsd1a) Single-dose Ba1ance Trial Shows Mrna-3745 Was Well Tolerated to Date.
Announces a New Development Candidate, Mrna-3139, for Ornithine Transcarbamylase (otc) Deficiency, a Rare Genetic Disorder.
Moderna - Phase 3 Immunogenicity and Safety Study of Flu Vaccine, Mrna-1010, is Fully Enrolled; Company to Pursue Accelerated Approval Pathway in 2023.company is on Track to Report Data From Its Phase 2 Personalized Cancer Vaccine (pcv) Study in 4q 2022.